A UK-based artificial intelligence (AI)-driven venture called Exscientia made a significant advancement involving the licensing of intellectual property in the form of an immune-modulating drug…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.